Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Amitiza launches in U.S. to treat chronic idiopathic constipation
May 18th, 2006
Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc., announced that Amitiza (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. Amitiza (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently. "Amitiza is an important new option for people living...
Source: Biotech Business Week (2006-05-18)
|
